The National Institute for Allergy and Infectious Diseases (NIAID) has been recognized by the FLC for their impact on the public through their technology transfer work. On February 21, 2020 NIAID’s Division of Microbiology and Infectious Diseases (DMID) started an Adaptive COVID-19 Treatment Trial (ACTT) to test Gilead’s antiviral drug remdesivir, in a phase 3 trial. Remdesivir is an inhibitor of the viral RNA polymerase, so it became an early therapeutic candidate for COVID-19. This was the first clinical trial in the U.S. for an experimental treatment for COVID-19. The FDA approved remdesivir for the treatment of COVID-19 patients on October 22, 2020, and it became the first therapy to receive FDA approval. For their work in initiating a large international clinical trial for a potential treatment within weeks of the discovery of SARS-CoV-2, submission name “Enable ACTT trial to test remdesivir as a COVID-19 treatment”, NIAID took home the award for Impact.